Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Dna Scns (NQ: APDN )

0.4033 +0.0033 (+0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied Dna Scns

< Previous 1 2 3 4 Next >
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
Via ACCESSWIRE
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
Via ACCESSWIRE
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
Via ACCESSWIRE
Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
Via ACCESSWIRE
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform
Via ACCESSWIRE
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
Via ACCESSWIRE
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Via ACCESSWIRE
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
Via ACCESSWIRE
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
Via ACCESSWIRE
Applied DNA Announces Pricing of $12 Million Public Offering
Via ACCESSWIRE
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
Via ACCESSWIRE
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
Via ACCESSWIRE
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
Applied DNA Announces 1-For-20 Reverse Stock Split
Via ACCESSWIRE
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
Via ACCESSWIRE
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
Exposures Cannabis
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
Via ACCESSWIRE
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
Via ACCESSWIRE
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
Via ACCESSWIRE
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
Via ACCESSWIRE
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
Via ACCESSWIRE
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
Via ACCESSWIRE
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
Via ACCESSWIRE
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
Via ACCESSWIRE
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
Via ACCESSWIRE
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
Via ACCESSWIRE
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.